Shenzhen Huikang Unveils Refreshed Brand Identity and Files IPO Prospectus

On September 5, 2025, the Huikang Brand Relaunch Event was successfully held at the Dornier/Huikang booth during the 32nd Congress of Urology (CUA 2025). Themed “Excellence in Intelligence, Empowering Health,” the event officially unveiled Huikang’s newly upgraded brand identity, marking a significant step forward in the company’s expansion of products and services in the international market. Mr. Wang Youcong, CEO of Advanced MedTech Group; Ms. Wu Qiong, General Manager of Dornier North Asia and Shenzhen Huikang; and Ms. Sylvia Briskorn, Senior Director of Global Product Marketing and Project Management at Dornier, attended the launch. Together with industry experts, partners, attendees, and exhibitors of CUA, they witnessed the relaunch of the Huikang brand.

 Figure 1: Zong Runwei, Marketing Director of Dornier North Asia and Shenzhen Huikang Company, hosted the press conference.

Figure 2: Unveiling of Huikang’s New Brand

Wang Youcong, CEO of Advanced MedTech Group, stated at the press conference: “Today, we are deeply honored to join you in witnessing this significant moment—the unveiling of Huikang’s new brand identity! As part of AMTH Group’s ongoing global expansion initiatives, the new brand embodies Huikang’s philosophy of ‘Excellence and Intelligence, Empowering Health.’ This logo reflects our four decades of deep-rooted commitment to the Chinese market, as well as our global vision forged through collaboration with top-tier international brands. Moving forward, we will continue to prioritize clinical value, delivering more accessible, reliable, and compassionate solutions for every treatment and every patient through sustained innovation, consistent quality, and solid service.”

 Figure 3: Address by Wang Youcong, Global CEO of Advanced MedTech Group

At the press conference, Wu Qiong, General Manager of Dornier’s North Asia Region and Shenzhen Huikang, stated: “The formation of our new brand identity stems from our commitment to serving patients, our like-minded collaboration with strategic partners such as Dornier, and our unwavering original aspiration to serve patients through innovative technology. The ‘Powered by Dornier’ designation in the new brand signifies the refinement of Huikang’s manufacturing processes. By leveraging Dornier’s profound expertise in shockwave technology, Huikang will achieve further growth, enabling the company to sustain continuous development in areas such as product development and realize its international expansion.”

 Figure 4: Address by Wu Qiong, General Manager of Dornier North Asia and Shenzhen Huikang

Figure 5: Group photo; keep up the good work

 Figure6: Dornier MedTech’s Booth at CUA 2025 (Booth A06, Level 1, Dalian International Convention Center)

Figure 7: Huikang's New Brand

Huikang’s new logo prominently features the phrase “Powered by Dornier MedTech,” building upon its original design. This update reflects Huikang’s commitment to harnessing Dornier’s empowerment, accumulating strength, driving continuous innovation, expanding its global footprint, and enhancing its influence in the international market.

In 2022, Huikang officially joined Advanced MedTech Holdings (AMTH), the holding company of Dornier MedTech, becoming a member of the AMTH Group. By forming a strategic alliance with Germany’s Dornier, the two parties have engaged in close collaboration in product research and development, quality control, academic promotion, and corporate management. This brand revitalization of Huikang is part of the AMTH Group’s global development strategy. Huikang will join hands with Dornier to further expand its presence in international markets, leveraging Dornier’s stronger global brand recognition to sell its products to more countries and regions.

This brand revitalization initiative delves deep into the core spirit of Huikang, distilling its brand vision as “Empowering Healthcare with Advanced Solutions.” It articulates Huikang’s commitment to leveraging continuous intelligence and innovation, in partnership with Dornier, to deliver superior healthcare solutions for patients and medical professionals worldwide.

A Time-Honored Brand, New Growth! Huikang stands as a cornerstone in China’s shockwave therapy equipment sector. Established in 1996, approximately 30 years ago, in Shenzhen—the cradle that has nurtured numerous innovative Chinese enterprises—Huikang came into being. As one of China’s medical technology brands specializing in extracorporeal shockwave lithotripsy, its product portfolio encompasses extracorporeal shockwave lithotripsy (ESWL) for urology, as well as extracorporeal shockwave therapy (ESWT) for rehabilitation, orthopedics, pain management, and the treatment of erectile dysfunction in andrology. To date, Huikang has served over 2,000 medical institutions across China, with its equipment distributed throughout the country and exported to more than 40 countries and regions overseas, achieving an impressive average annual operational uptime rate of 98%!

Dornier MedTech, the inventor of shockwave technology, launched the first shockwave lithotripter for human use in 1980, marking 45 years of history. As a pioneer in the field of extracorporeal shockwave lithotripsy (ESWL), Dornier’s innovative technologies have been widely adopted by numerous top-tier medical institutions worldwide, with millions of treatments performed to date. Following Dornier MedTech’s invention of this technology, Huikang became one of the earliest companies in China to introduce it. Since 1989, Huikang has been dedicated to the research and development of shockwave lithotripters, continuously improving its products in line with Dornier’s technological advancements. Through the strategic partnership between Huikang and Dornier, both parties will work together to empower each other, with the long-term goal of meeting patient needs. By integrating their respective strengths in medical technology, market channels, and clinical resources, they will further leverage their core competencies and optimize product portfolios to address the demands of diverse markets.

Strategic Partnership Begins to Yield Results. This June, the Huikang U200 Extracorporeal Shock Wave Lithotripter successfully obtained clearance from the U.S. Food and Drug Administration (FDA) under the 510(k) pathway. This significant milestone marks a pivotal turning point in Huikang’s international expansion and stands as a testament to the dedicated collaboration, professional expertise, and shared vision of Huikang, Dornier, and the Advanced MedTech global team.

Figure 8: Huikang U200

The relaunch of the Huikang brand will further strengthen its competitiveness in the international market and accelerate the global promotion and application of its products. In the future, Huikang will continue to push technological boundaries, committing to delivering higher-precision, superior-quality medical solutions. By joining forces with Dornier to drive collaborative innovation and continuously enrich its product portfolio, Huikang aims to provide high-quality solutions for patients worldwide.

Huikang is dedicated to the research, development, and manufacturing of extracorporeal shock wave medical devices, including extracorporeal shock wave lithotripsy (ESWL) for urinary calculi, extracorporeal shock wave therapy (ESWT) in orthopedics, rehabilitation, and pain management, treatment for erectile dysfunction, and stone expulsion beds. Huikang is recognized as a National High-Tech Enterprise in China, hosts a Key Engineering Laboratory in Shenzhen, serves as the Guangdong Provincial Engineering Technology Research Center for Medical Shock Wave Therapy Equipment, and is designated as a Guangdong Provincial Specialized, Refined, Differential, and Innovative Enterprise.

Dornier MedTech is a multinational medical device company headquartered in Munich, Germany. As a wholly-owned subsidiary of Advanced MedTech Holdings, it is the pioneer of extracorporeal shock wave lithotripsy (ESWL) equipment and technology. Driven by entrepreneurial spirit and an unwavering pursuit of excellence, Dornier is committed to continuous innovation in urology, developing high-quality urological and shock wave therapy devices currently available on the market. Dornier remains dedicated to serving its extensive customer base and improving outcomes for patients worldwide.

Advanced MedTech Holdings (AMTH) is one of the earliest companies globally to achieve full industry chain integration in urology, driving innovation in urological care through minimally invasive solutions and a global footprint. Headquartered in Singapore, with operations in over 100 countries, the company is a leading market player in lithotripsy and operates the world’s largest online urology community. By combining German engineering excellence with advanced digital and clinical capabilities, the Group aims to improve patient outcomes and support healthcare professionals across the continuum of care. Its brand portfolio includes well-known names such as Dornier MedTech, WIKKON, Northern Litho, NextMed, and AMT Manufacturing. With more than 1,000 employees worldwide, AMTH is committed to expanding its influence through strategic investments in R&D, manufacturing, and partnerships, advancing standards in endourological care and shaping the future of medical technology.

This announcement may contain general information about products and services. The availability, approved indications, and labeling/instructions for such products or services may vary depending on local regulatory approvals in different markets, and clinical outcomes may differ across various healthcare settings and patient characteristics. This does not constitute a guarantee of product efficacy. This announcement may also include statements regarding market position and forward-looking statements based on the current views and assumptions of the issuing entity. Such statements are subject to known and unknown risks, uncertainties, and other factors—most of which are beyond our control—that may cause actual results to differ materially from those expressed or implied. These statements are provided “as is” and do not constitute a guarantee of future performance. Readers are advised to exercise caution and avoid placing undue reliance on them. Except as required by applicable law, we assume no obligation to update any information contained in this announcement.